Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019057 | 0.91 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL14744213 | 0.90 | MEN1 (0.66) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL754326 | 0.90 | MEN1 (0.66) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23690865 | 0.86 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17452213 | 0.86 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL8194926 | 0.86 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL22433494 | 0.86 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL16917206 | 0.84 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL1022696 | 0.84 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17144126 | 0.84 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908759-B1 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2012-03-21 | — | — | EP | disclosed |
| EP-1908760-B1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| EP-1911757-B1 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | BIAL - PORTELA & CA S.A. (PT) | 2010-11-11 | — | — | US | disclosed |
| EP-2111262-A2 | 1,3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-10-28 | — | — | EP | disclosed |
| EP-1408038-B1 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | BIAL PORTELA & CA SA (PT) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008085074-A2 | 1, 3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA., S.A. (PT) | 2008-07-17 | — | — | WO | disclosed |
| CN-100393715-C | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | PORTELA & CA SA (PT) | 2008-06-11 | — | — | CN | disclosed |
| EP-1914233-A1 | Peripherally-selective inhibitors of dopamine-b-hydroxylase and method of their preparation | Portela & Ca., S.A. (PT) | 2008-04-23 | — | — | EP | disclosed |
| EP-1911757-A2 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | Portela & Ca., S.A. (PT) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908759-A2 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| CN-1726211-A | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | PORTELA & CA SA (PT) | 2006-01-25 | — | — | CN | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | MEN1 3669/4885GAA 2321/4885KMT2A 2388/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | MEN1 3745/4885GAA 1946/4885KMT2A 744/4885 |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | HTR1F, HTR1D, ADRB3 | MEN1 453/4885GAA 3491/4885KMT2A 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.